WHO gives further support to Bavarian Nordic and Johnson & Johnson's Ebola vaccine

A WHO committee has updated its recommendations with good news for Johnson & Johnson and Bavarian Nordic's two-dose Ebola vaccine.

Photo: Mads Nissen/STF

The latest recommendations from the World Health Organization (WHO) support the use of Johnson & Johnson and Bavarian Nordic's two-dose vaccine regimen against Ebola virus, according to a Monday press release.

WHO's Strategic Advisory Group of Experts on Immunization (SAGE) has extended its support for the vaccine.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs